(SNN) Smith & Nephew SNATS - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

Orthopedic Implants, Surgical Instruments, Wound Care, Reconstructive Devices

SNN EPS (Earnings per Share)

EPS (Earnings per Share) of SNN over the last years for every Quarter: "2020-03": 0.06, "2020-06": 0.11, "2020-09": 0.2, "2020-12": 0.4, "2021-03": 0.12, "2021-06": 0.23, "2021-09": 0.18, "2021-12": 0.36, "2022-03": 0.1, "2022-06": 0.2, "2022-09": 0.03, "2022-12": 0.05, "2023-03": 0.1, "2023-06": 0.4, "2023-09": 0.05, "2023-12": 0.1, "2024-03": 0.12, "2024-06": 0.49, "2024-12": 0.45,

SNN Revenue

Revenue of SNN over the last years for every Quarter: 2020-03: 1017.5, 2020-06: 2035, 2020-09: 1262.5, 2020-12: 2525, 2021-03: 1299.5, 2021-06: 2599, 2021-09: 1306.5, 2021-12: 2613, 2022-03: 1300, 2022-06: 2600, 2022-09: 1307.5, 2022-12: 2615, 2023-03: 1367, 2023-06: 2734, 2023-09: 1407.5, 2023-12: 2815, 2024-03: 1413.5, 2024-06: 2827, 2024-12: 2983,

Description: SNN Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company that develops, manufactures, and markets a diverse range of medical devices and services across three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The companys product portfolio includes knee and hip implants, trauma and extremities products, sports medicine joint repair products, arthroscopic enabling technologies, and advanced wound care products. With a presence in the UK, US, and internationally, Smith & Nephew serves healthcare providers with innovative solutions for various medical conditions, including joint replacement, soft tissue injuries, and wound care.

Notably, the companys Orthopaedics segment offers a range of implant products for knee and hip replacement procedures, as well as trauma and extremities products for fracture stabilization and deformity correction. The Sports Medicine & ENT segment provides minimally invasive surgical solutions, including arthroscopic enabling technologies and ear, nose, and throat solutions. Meanwhile, the Advanced Wound Management segment offers a range of products for wound care, including bioactive technologies, negative pressure wound therapy, and hydrosurgery systems.

From a technical analysis perspective, Smith & Nephews stock (SNN) is currently trading at $30.30, with a 20-day SMA of $28.82, a 50-day SMA of $27.72, and a 200-day SMA of $27.13. The stocks ATR is $0.50, indicating a relatively low volatility. Given the current technical setup, a potential forecast is that the stock may continue to trend upwards, potentially reaching the 52-week high of $30.83, driven by the companys strong product portfolio and growing demand for its medical devices and services.

Fundamentally, Smith & Nephews market capitalization stands at $12.52 billion, with a P/E ratio of 30.44 and a forward P/E of 13.37. The companys RoE is 11.68%, indicating a relatively stable return on equity. Considering the fundamental data, a forecast is that Smith & Nephews stock may experience a moderate increase in value, driven by the companys continued innovation and expansion in the global healthcare market. With a strong product pipeline and a solid financial position, the company is well-positioned to capitalize on growing demand for its products and services.

Combining both technical and fundamental analysis, a potential forecast is that Smith & Nephews stock may reach $32.50 within the next 6-12 months, driven by a combination of its strong product portfolio, growing demand, and favorable technical trends. However, this forecast is contingent on various factors, including the companys ability to continue innovating and expanding its market share, as well as overall market conditions.

Additional Sources for SNN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

SNN Stock Overview

Market Cap in USD 13,222m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 1999-11-16

SNN Stock Ratings

Growth Rating -27.1
Fundamental 52.6
Dividend Rating 38.3
Rel. Strength 21.5
Analysts 3.75 of 5
Fair Price Momentum 30.24 USD
Fair Price DCF 41.85 USD

SNN Dividends

Dividend Yield 12m 2.57%
Yield on Cost 5y 2.14%
Annual Growth 5y 0.00%
Payout Consistency 95.3%
Payout Ratio 79.8%

SNN Growth Ratios

Growth Correlation 3m 91.7%
Growth Correlation 12m -1%
Growth Correlation 5y -64.8%
CAGR 5y -2.88%
CAGR/Max DD 5y -0.06
Sharpe Ratio 12m 1.33
Alpha 16.59
Beta 0.271
Volatility 25.07%
Current Volume 274.9k
Average Volume 20d 854.9k
What is the price of SNN shares?
As of July 06, 2025, the stock is trading at USD 30.28 with a total of 274,900 shares traded.
Over the past week, the price has changed by +0.20%, over one month by +3.45%, over three months by +15.09% and over the past year by +15.92%.
Is Smith & Nephew SNATS a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Smith & Nephew SNATS (NYSE:SNN) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.58 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNN is around 30.24 USD . This means that SNN is currently overvalued and has a potential downside of -0.13%.
Is SNN a buy, sell or hold?
Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold SNN.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for SNN share price target?
According to our own proprietary Forecast Model, SNN Smith & Nephew SNATS will be worth about 32.9 in July 2026. The stock is currently trading at 30.28. This means that the stock has a potential upside of +8.78%.
Issuer Target Up/Down from current
Wallstreet Target Price 33.2 9.5%
Analysts Target Price 33.2 9.5%
ValueRay Target Price 32.9 8.8%